Nycomed US names new CEO

Markison will also be a member of the board of the newly created standalone company, following the completion of the acquisition of Nycomed A/S by Takeda Pharmaceuticals.

Previously, Markison worked as the chairman and CEO of King Pharmaceuticals.

Prior to King Pharma, he has held leadership positions at Bristol-Myers Squibb, including president of Oncology / Virology and Oncology Therapeutics Network; president – Neuroscience / Infectious Disease and Dermatology; and senior vice president, Operational Excellence and Productivity.

Nycomed CEO Hakan Bjorklund said they have full confidence that Brian’s broad experience, stature in the industry and proven record of success make him the right person to lead Nycomed US as it becomes a standalone company and meets the challenges of the future.